skip to main content
Idioma:

HER3/ErbB3, an emerging cancer therapeutic target

Zhang, Ningyan ; Chang, Yujun ; Rios, Adan ; An, Zhiqiang

Acta biochimica et biophysica Sinica, 2016-01, Vol.48 (1), p.39-48 [Periódico revisado por pares]

China

Texto completo disponível

Citações Citado por
  • Título:
    HER3/ErbB3, an emerging cancer therapeutic target
  • Autor: Zhang, Ningyan ; Chang, Yujun ; Rios, Adan ; An, Zhiqiang
  • Assuntos: Animals ; Antibodies, Monoclonal - chemistry ; Antineoplastic Agents - chemistry ; Biomarkers, Tumor - metabolism ; EGFR ; Endosomal Sorting Complexes Required for Transport - metabolism ; Humans ; Mutation ; Nedd4 Ubiquitin Protein Ligases ; Neoplasms - drug therapy ; Neoplasms - genetics ; Neoplasms - metabolism ; Neuregulin-1 - metabolism ; Oligonucleotides, Antisense - genetics ; Protein Multimerization ; Receptor, Epidermal Growth Factor - metabolism ; Receptor, ErbB-3 - metabolism ; Signal Transduction ; Ubiquitin-Protein Ligases - metabolism ; 临床疗效 ; 单克隆抗体 ; 生物标志物 ; 癌症患者 ; 肿瘤治疗 ; 跨膜受体 ; 靶点
  • É parte de: Acta biochimica et biophysica Sinica, 2016-01, Vol.48 (1), p.39-48
  • Notas: 31-1940/Q
    HER3/ErbB3, monoclonal antibody （mAb）, biomarkers, cancer therapy
    HER3 is a member of the HER （EGFR/ErbB） receptor family consisting of four closely related type 1 transmembrane receptors （EGFR, HER2, HER3, and HER4）. HER receptors are part of a complex sig- naling network intertwined with the Ras/Raf/MAPK, PI3K/AKT, JAK/STAT, and PKC signaling path- ways. Aberrant activation of the HER receptors and downstream signaling molecules tips the balance on cellular events, leading to various types of cancers. Monoclonal antibodies （mAbs） and small molecule inhibitors targeting EGFR and HER2 tyrosine kinase activities exhibit clinical ben- efits in the treatment of several types of cancers, but their clinical efficacy is limited by the occurrence of drug resistance. HER3 is the preferred dimerization partner of HER2 and it is well established that HER3 plays an important role in drug resistance to EGFR- and HER2-targeting therapies. Since HER3 has limited kinase activity, mAbs are being explored to target HER3 for cancer therapy. Currently, approximately a dozen of anti-HER3 mAbs are at different stages of clinical development. However, the lack of established biomarkers has made it more challenging to stratify cancer patients to whom HER3-targeting therapies can be more effective. In this review, we focus on the validation of HER3 as a cancer drug target, the recent development in biomarker discovery for anti-HER3 therapies, and the progress made in the clinical development of HER3-targeting mAbs.
    ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
    ObjectType-Article-1
    ObjectType-Feature-2
  • Descrição: HER3 is a member of the HER （EGFR/ErbB） receptor family consisting of four closely related type 1 transmembrane receptors （EGFR, HER2, HER3, and HER4）. HER receptors are part of a complex sig- naling network intertwined with the Ras/Raf/MAPK, PI3K/AKT, JAK/STAT, and PKC signaling path- ways. Aberrant activation of the HER receptors and downstream signaling molecules tips the balance on cellular events, leading to various types of cancers. Monoclonal antibodies （mAbs） and small molecule inhibitors targeting EGFR and HER2 tyrosine kinase activities exhibit clinical ben- efits in the treatment of several types of cancers, but their clinical efficacy is limited by the occurrence of drug resistance. HER3 is the preferred dimerization partner of HER2 and it is well established that HER3 plays an important role in drug resistance to EGFR- and HER2-targeting therapies. Since HER3 has limited kinase activity, mAbs are being explored to target HER3 for cancer therapy. Currently, approximately a dozen of anti-HER3 mAbs are at different stages of clinical development. However, the lack of established biomarkers has made it more challenging to stratify cancer patients to whom HER3-targeting therapies can be more effective. In this review, we focus on the validation of HER3 as a cancer drug target, the recent development in biomarker discovery for anti-HER3 therapies, and the progress made in the clinical development of HER3-targeting mAbs.
  • Editor: China
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.